Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women

BASBUG, Mustafa; AYGEN, ERCAN; TAYYAR, MEHMET; Muhtaroglu, SABAHATTİN; Demir, I; OKTEN, Süheyl

doi:10.1016/s0301-2115(97)02706-1

Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women

Atıf İçin Kopyala

BASBUG M., AYGEN E. M., TAYYAR M., Muhtaroglu S., Demir I., OKTEN S.

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, cilt.73, sa.2, ss.149-152, 1997 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 73 Sayı: 2
Basım Tarihi: 1997
Doi Numarası: 10.1016/s0301-2115(97)02706-1
Dergi Adı: EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.149-152
Anahtar Kelimeler: transdermal estradiol, conjugated estrogen, sex hormone-binding globulin, breast cancer, cardiovascular disease, ESTROGEN REPLACEMENT THERAPY, GROWTH-FACTOR-I, POSTMENOPAUSAL WOMEN, PLASMA, SERUM, 17-BETA-ESTRADIOL, PROGESTOGENS
Erciyes Üniversitesi Adresli: Evet

Özet

Objective: To compare the effects of continuous noncombined transdermal estradiol versus oral conjugated estrogen on serum sex hormone-binding globulin (SHBG) levels prior to and during the 10th and 22nd weeks of therapy in patients with surgical menopause. Study design: Open, comparative trial. Patients were consecutively assigned to three groups: group 1 (n=18) received continuous transdermal estradiol (0.050 mg/day), group 2 (n=18) continuous oral conjugated estrogens (0.625 mg/day), whereas group 3 (n=15) received no treatment. Serum SHBG levels were determined before treatment and after 10 and 22 weeks of treatment. Results: Serum SHBG increased significantly with oral conjugated estrogens at 10 (p<0.01) and 22 weeks (p<0.01) compared with baseline. With transdermal estrogens there was a much smaller increase of SHBG. At 22 weeks, this increase was significant compared with baseline (p<0.05), but not compared with the control group (p>0.05). Conclusion: Transdermal estrogen has no effect on SHBG, whereas oral conjugated estrogens causes a considerable increase. (C) 1997 Elsevier Science Ireland Ltd.